Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak

Human parthenogenetic stem cells (hpSCs) are pluripotent stem cells with enormous potential as cell sources for cell-based therapies: hpSCs may have histocompatibilty advantages over human embryonic stem cells (hESCs) and derivation of hpSCs does not require viable blastocyst destruction. For transl...

Full description

Bibliographic Details
Main Authors: Nikolay Turovets, Jeffrey Fair, Richard West, Alina Ostrowska, Ruslan Semechkin, Jeffrey Janus, Li Cui, Vladimir Agapov, Irina Turovets, Andrey Semechkin, Marie Csete, Larissa Agapova
Format: Article
Language:English
Published: SAGE Publishing 2012-02-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368911X582723
id doaj-da85ac516c464d5ab385584c549b9739
record_format Article
spelling doaj-da85ac516c464d5ab385584c549b97392020-11-25T03:02:54ZengSAGE PublishingCell Transplantation0963-68971555-38922012-02-012110.3727/096368911X582723Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive StreakNikolay Turovets0Jeffrey Fair1Richard West2Alina Ostrowska3Ruslan Semechkin4Jeffrey Janus5Li Cui6Vladimir Agapov7Irina Turovets8Andrey Semechkin9Marie Csete10Larissa Agapova11International Stem Cell Corporation, Oceanside, CA, USACedars-Sinai Medical Center, Los Angeles, CA, USAWest Labs Scientific, Grand Rapids, MI, USAInternational Stem Cell Corporation, Oceanside, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAOrganovo, San Diego, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAOrganovo, San Diego, CA, USAInternational Stem Cell Corporation, Oceanside, CA, USAHuman parthenogenetic stem cells (hpSCs) are pluripotent stem cells with enormous potential as cell sources for cell-based therapies: hpSCs may have histocompatibilty advantages over human embryonic stem cells (hESCs) and derivation of hpSCs does not require viable blastocyst destruction. For translation of all pluripotent stem cell-based therapies, derivation of differentiated cell products that are not contaminated with undifferentiated cells is a major technical roadblock. We report here a novel method to derive high-purity definitive endoderm (DE) from hpSCs, based on reproducing features of the normal human embryonic microenvironment. The method mimics the developmental process of transition through a primitive streak, using a differentiation device that incorporates a three-dimensional extracellular matrix (ECM) combined with a porous membrane. Treatment of undifferentiated hpSCs above the membrane results an epithelial-to-mesenchymal transition (EMT); thus, responsive cells acquire the ability to migrate through the membrane into the ECM, where they differentiate into DE. Importantly, the resultant DE is highly purified, and is not contaminated by undifferentiated cells, as assessed by OCT4 expression using immunocytochemistry and flow cytometry. The functional properties of the DE are also preserved by the process: DE differentiated in the device can generate a highly enriched population of hepatocyte-like cells (HLCs) characterized by expression of hepatic lineage markers, indocyanine green clearance, glycogen storage, cytochrome P450 activity, and engraftment in the liver after transplantation into immunodeficient mice. The method is broadly applicable and we obtained purified DE using hESCs, as well as several hpSC lines. The novel method described here represents a significant step toward the efficient generation of high-purity cells derived from DE, including hepatocytes and pancreatic endocrine cells, for use in regenerative medicine and drug discovery, as well as a platform for studying cell fate specification and behavior during development.https://doi.org/10.3727/096368911X582723
collection DOAJ
language English
format Article
sources DOAJ
author Nikolay Turovets
Jeffrey Fair
Richard West
Alina Ostrowska
Ruslan Semechkin
Jeffrey Janus
Li Cui
Vladimir Agapov
Irina Turovets
Andrey Semechkin
Marie Csete
Larissa Agapova
spellingShingle Nikolay Turovets
Jeffrey Fair
Richard West
Alina Ostrowska
Ruslan Semechkin
Jeffrey Janus
Li Cui
Vladimir Agapov
Irina Turovets
Andrey Semechkin
Marie Csete
Larissa Agapova
Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
Cell Transplantation
author_facet Nikolay Turovets
Jeffrey Fair
Richard West
Alina Ostrowska
Ruslan Semechkin
Jeffrey Janus
Li Cui
Vladimir Agapov
Irina Turovets
Andrey Semechkin
Marie Csete
Larissa Agapova
author_sort Nikolay Turovets
title Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
title_short Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
title_full Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
title_fullStr Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
title_full_unstemmed Derivation of High-Purity Definitive Endoderm from Human Parthenogenetic Stem Cells Using an in Vitro Analog of the Primitive Streak
title_sort derivation of high-purity definitive endoderm from human parthenogenetic stem cells using an in vitro analog of the primitive streak
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2012-02-01
description Human parthenogenetic stem cells (hpSCs) are pluripotent stem cells with enormous potential as cell sources for cell-based therapies: hpSCs may have histocompatibilty advantages over human embryonic stem cells (hESCs) and derivation of hpSCs does not require viable blastocyst destruction. For translation of all pluripotent stem cell-based therapies, derivation of differentiated cell products that are not contaminated with undifferentiated cells is a major technical roadblock. We report here a novel method to derive high-purity definitive endoderm (DE) from hpSCs, based on reproducing features of the normal human embryonic microenvironment. The method mimics the developmental process of transition through a primitive streak, using a differentiation device that incorporates a three-dimensional extracellular matrix (ECM) combined with a porous membrane. Treatment of undifferentiated hpSCs above the membrane results an epithelial-to-mesenchymal transition (EMT); thus, responsive cells acquire the ability to migrate through the membrane into the ECM, where they differentiate into DE. Importantly, the resultant DE is highly purified, and is not contaminated by undifferentiated cells, as assessed by OCT4 expression using immunocytochemistry and flow cytometry. The functional properties of the DE are also preserved by the process: DE differentiated in the device can generate a highly enriched population of hepatocyte-like cells (HLCs) characterized by expression of hepatic lineage markers, indocyanine green clearance, glycogen storage, cytochrome P450 activity, and engraftment in the liver after transplantation into immunodeficient mice. The method is broadly applicable and we obtained purified DE using hESCs, as well as several hpSC lines. The novel method described here represents a significant step toward the efficient generation of high-purity cells derived from DE, including hepatocytes and pancreatic endocrine cells, for use in regenerative medicine and drug discovery, as well as a platform for studying cell fate specification and behavior during development.
url https://doi.org/10.3727/096368911X582723
work_keys_str_mv AT nikolayturovets derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT jeffreyfair derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT richardwest derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT alinaostrowska derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT ruslansemechkin derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT jeffreyjanus derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT licui derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT vladimiragapov derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT irinaturovets derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT andreysemechkin derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT mariecsete derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
AT larissaagapova derivationofhighpuritydefinitiveendodermfromhumanparthenogeneticstemcellsusinganinvitroanalogoftheprimitivestreak
_version_ 1724687805859233792